Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.67 |
| ▸ | EP300 | Q09472 | 1/20 | 0.60 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17798097 | 1.00 | BRD4 (0.67) | BRD4EP300CREBBP | |
| SCHEMBL17798075 | 0.90 | BRD4 (0.74) | BRD4EP300CREBBP | |
| SCHEMBL29921057 | 0.90 | BRD4 (0.74) | BRD4EP300CREBBP | |
| SCHEMBL31499253 | 0.89 | BRD4 (0.78) | BRD4EP300CREBBP | |
| SCHEMBL16347875 | 0.89 | BRD4 (0.62) | BRD4EP300CREBBP | |
| SCHEMBL29920777 | 0.89 | BRD4 (0.62) | BRD4EP300CREBBP | |
| SCHEMBL17798032 | 0.86 | BRD4 (0.58) | BRD4EP300CREBBP | |
| SCHEMBL29920746 | 0.86 | BRD4 (0.66) | BRD4EP300CREBBP | |
| SCHEMBL16347499 | 0.86 | BRD4 (0.66) | BRD4EP300CREBBP | |
| SCHEMBL31499233 | 0.85 | BRD4 (0.63) | BRD4EP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3674300-B1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2022-10-12 | — | — | EP | disclosed |
| US-11446306-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446306-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | BRD4 1/4885EP300 15/4885CREBBP 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.